Navigation Links
Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine

Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in... -- OXFORD, England, November 18, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine


OXFORD, England, November 18, 2010 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful clinical results from a phase II study of its T-cell vaccine targeting house dust mite allergy. The study met each of the safety and efficacy endpoints, with the optimal treatment regimen achieving a major reduction in patients' reactions to house dust mite allergens. These results build on four earlier successful phase II studies of Circassia's ToleroMune(R) technology, which scientifically validated the use of novel T-cell vaccines in treating allergies. Circassia is currently conducting a number of ongoing phase II clinical trials with its therapies for grass (hayfever), cat and ragweed allergies.

Circassia undertook its most recent phase II clinical study in Quebec City, Canada, in 50 patients with confirmed house dust mite allergies. Patients received four standardised doses of ToleroMune T-cell vaccine over a number of weeks. During the study, investigators administered a challenge dose of house dust mite allergen to the volunteers' skin and eyes to assess the impact of the ToleroMune therapy. The results show that the optimal treatment regimen reduced each of the allergic reactions assessed during the study, achieving a therapeutic effect 32% - 87% greater than placebo.

"These positive clinical results, achieved with our house dust mite allergy treatment, are particularly encouraging as they mirror those from earlier successful studies with our cat and ragweed allergy therapies," said Steve Harris, Circassia's CEO. "Our rapidly growing clinical database clearly demonstrates the potential of Circassia's T-cell vaccines to greatly improve allergy treatment, by offering sufferers a convenient and well tolerated alternative to existing immunotherapies. We have made significant progress in advancing a number of allergy T-cell vaccines into mid- to late-stage development, and we continue to work hard to bring these innovative therapies to market as quickly as possible."

About Circassia's allergy T-cell vaccines

Circassia's range of allergy T-cell vaccines is based on its proprietary ToleroMune(R) technology. This technology utilises allergen epitopes to generate regulatory T cells that suppress allergic immune responses. Clinical results with Circassia's allergy T-cell vaccines show that short treatment regimes can greatly reduce patients' allergic reactions, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated. As a result, the company's allergy treatments offer major potential clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potential regulatory and supply chain benefits. The short peptides utilised in Circassia's vaccines are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the manufacturing and quality standards associated with conventional pharmaceuticals to its allergy T-cell vaccines. This fits with changes in the European regulatory environment, where authorities increasingly require the elimination of batch-to-batch potency variability that is an intrinsic feature of many current treatments.

About Circassia

Circassia has a highly experienced management team with a proven track record in product development and commercialisation. Having successfully completed three fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Invesco Perpetual, Goldman Sachs and Lansdowne Partners.

Contacts Steve Harris CEO Circassia Tel: +44(0)1865-784574 Rob Budge RJB Communications Tel: +44(0)1865-760969 Mobile: +44(0)7710-741241

SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
2. Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round
3. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
4. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
5. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
6. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
7. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
8. HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCE
9. XStor Medical Achieves ISO 13485 Certification
10. Stereotaxis Achieves Intellectual Property Milestone With 100th U.S. Patent
11. Omnicells OmniCenter Achieves VMware Ready(TM) Healthcare Virtualization Status
Post Your Comments:
(Date:11/30/2015)... -- Kevin Smith has been appointed Chief Commercial Officer ... wireless monitoring of vital signs.  As CCO based ... Smith will be responsible for the development and ... also directly oversee partnering with US hospitals and ... the first early warning detection device to be ...
(Date:11/30/2015)... Nov. 30, 2015  The fee-for-service reimbursement ... U.S. medical imaging is on its way ... care payer-provider contracts are set to phase ... wake, alter provider-vendor relationships. The shift to ... forward new purchasing frameworks in the medical ...
(Date:11/30/2015)... SAN DIEGO , Nov. 30, 2015 ... ARNA ) today announced that the U.S. Food ... New Drug Application (NDA) for an extended release formulation ... offer patients a chronic weight management treatment in a ... currently approved as an adjunct to a reduced-calorie diet ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... The Progressive Dental Institute ... 29 and 30, 2016. The course welcomes dental professionals and members of their ... how to better succeed in the modern dental marketplace. The course combines presentations ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus ... State University. , Their study showed that small molecule analogs that target the ...
(Date:11/30/2015)... NJ (PRWEB) , ... November 30, 2015 , ... Dr. ... With three office locations, patients can visit Dr. Margulies to experience the best available ... to hold the title of "NJ Top Dentist"! , Orthodontics is the branch of ...
(Date:11/30/2015)... ... November 30, 2015 , ... ”Dying Words: The AIDS Reporting ... on December 1, 2015, to coincide with World AIDS Day. The multi-media project will ... covered the AIDS epidemic as he was dying of the disease. , A collaborative ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to RF Safe, the ... scientist at Consumer Reports as supporting a “A Call for Clarity” on cell ... The original Nov 2015 CR story titled, “Does Cell-Phone Radiation Cause Cancer?” ...
Breaking Medicine News(10 mins):